CFO & COO of Pyxis Oncology Pamela Connealy Buys 13% More Shares
A Quick Look at Today's Ratings for Pyxis Oncology(PYXS.US), With a Forecast Between $7 to $10
Institutional Investors in Pyxis Oncology, Inc. (NASDAQ:PYXS) See US$130m Decrease in Market Cap Last Week, Although Long-term Gains Have Benefitted Them.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Sector Update: Health Care Stocks Advance Late Afternoon
Sector Update: Health Care
Pyxis Oncology Shares Slump After William Blair Downgrade
Dow Jumps Over 100 Points; Nvidia Posts Upbeat Earnings
Pyxis Oncology Is Maintained at Outperform by RBC Capital
RBC Ups Pyxis Oncology Target, Says Buy Shares on Selloff
Express News | Market-Moving News for November 21st
RBC Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Raises Target Price to $10
Pyxis Oncology Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Pyxis Oncology Analyst Ratings
Pyxis Oncology Reported 'Compelling' Cancer Dataset, Says H.C. Wainwright
RBC Boosts Price Target on Pyxis Oncology to $10 From $7, Keeps Outperform, Speculative Risk
William Blair Initiates Pyxis Oncology(PYXS.US) With Hold Rating
Biggest Stock Movers Thursday: NVDA, PANW, and More
Express News | Pyxis Oncology Inc : William Blair Cuts to Market Perform
Trending Stocks Today | Wag! Group Soars 83.72% Post-Market